Focused on determining the mechanisms of human disease and advancing new technologies to translate these insights into therapeutics through in-house biotech.
Arena BioWorks, a $500 million biotechnology start-up, is proving a fresh headache for embattled Harvard as it lures away its top academics with seven-figure payouts.